| Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes JA Dubovsky, KA Beckwith, G Natarajan, JA Woyach, S Jaglowski, ... Blood, The Journal of the American Society of Hematology 122 (15), 2539-2549, 2013 | 828 | 2013 |
| BTKC481S-Mediated Resistance to Ibrutinib in Chronic Lymphocytic Leukemia JA Woyach, AS Ruppert, D Guinn, A Lehman, JS Blachly, A Lozanski, ... Journal of Clinical Oncology 35 (13), 1437-1443, 2017 | 498 | 2017 |
| Ibrutinib treatment improves T cell number and function in CLL patients M Long, K Beckwith, P Do, BL Mundy, A Gordon, AM Lehman, ... The Journal of clinical investigation 127 (8), 3052-3064, 2017 | 355 | 2017 |
| Targeting the C481S ibrutinib-resistance mutation in Bruton’s tyrosine kinase using PROTAC-mediated degradation AD Buhimschi, HA Armstrong, M Toure, S Jaime-Figueroa, TL Chen, ... Biochemistry 57 (26), 3564-3575, 2018 | 320 | 2018 |
| Chronic stress and susceptibility to skin cancer AN Saul, TM Oberyszyn, C Daugherty, D Kusewitt, S Jones, S Jewell, ... Journal of the National Cancer Institute 97 (23), 1760-1767, 2005 | 271 | 2005 |
| Techniques for handling missing data in secondary analyses of large surveys DL Langkamp, A Lehman, S Lemeshow Academic pediatrics 10 (3), 205-210, 2010 | 257 | 2010 |
| Combination therapy with anti–CTL antigen-4 and anti-4-1BB antibodies enhances cancer immunity and reduces autoimmunity E Kocak, K Lute, X Chang, KF May Jr, KR Exten, H Zhang, ... Cancer research 66 (14), 7276-7284, 2006 | 236 | 2006 |
| The novel plant-derived agent silvestrol has B-cell selective activity in chronic lymphocytic leukemia and acute lymphoblastic leukemia in vitro and in vivo DM Lucas, RB Edwards, G Lozanski, DA West, JD Shin, MA Vargo, ... Blood, The Journal of the American Society of Hematology 113 (19), 4656-4666, 2009 | 228 | 2009 |
| Ibrutinib treatment ameliorates murine chronic graft-versus-host disease JA Dubovsky, R Flynn, J Du, BK Harrington, Y Zhong, B Kaffenberger, ... The Journal of clinical investigation 124 (11), 4867-4876, 2014 | 213 | 2014 |
| Targeting CD37-positive lymphoid malignancies with a novel engineered small modular immunopharmaceutical X Zhao, R Lapalombella, T Joshi, C Cheney, A Gowda, ... Blood, The Journal of the American Society of Hematology 110 (7), 2569-2577, 2007 | 203 | 2007 |
| Hypermorphic mutation of phospholipase C, γ2 acquired in ibrutinib-resistant CLL confers BTK independency upon B-cell receptor activation TM Liu, JA Woyach, Y Zhong, A Lozanski, G Lozanski, S Dong, E Strattan, ... Blood, The Journal of the American Society of Hematology 126 (1), 61-68, 2015 | 200 | 2015 |
| FTY720 demonstrates promising preclinical activity for chronic lymphocytic leukemia and lymphoblastic leukemia/lymphoma Q Liu, X Zhao, F Frissora, Y Ma, R Santhanam, D Jarjoura, A Lehman, ... Blood, The Journal of the American Society of Hematology 111 (1), 275-284, 2008 | 187 | 2008 |
| The activation of natural killer cell effector functions by cetuximab-coated, epidermal growth factor receptor–positive tumor cells is enhanced by cytokines JM Roda, T Joshi, JP Butchar, JW McAlees, A Lehman, S Tridandapani, ... Clinical Cancer Research 13 (21), 6419-6428, 2007 | 185 | 2007 |
| Epidemiology and risk factors for thromboembolic complications of childhood nephrotic syndrome: a Midwest Pediatric Nephrology Consortium (MWPNC) study BA Kerlin, NB Blatt, B Fuh, S Zhao, A Lehman, C Blanchong, JD Mahan, ... The Journal of pediatrics 155 (1), 105-110. e1, 2009 | 182 | 2009 |
| Higher doses of lenalidomide are associated with unacceptable toxicity including life-threatening tumor flare in patients with chronic lymphocytic leukemia LA Andritsos, AJ Johnson, G Lozanski, W Blum, C Kefauver, F Awan, ... Journal of Clinical Oncology 26 (15), 2519-2525, 2008 | 177 | 2008 |
| IgG subclass staining in renal biopsies with membranous glomerulonephritis indicates subclass switch during disease progression CC Huang, A Lehman, A Albawardi, A Satoskar, S Brodsky, G Nadasdy, ... Modern Pathology 26 (6), 799-805, 2013 | 176 | 2013 |
| Characterization of CLL exosomes reveals a distinct microRNA signature and enhanced secretion by activation of BCR signaling YY Yeh, HG Ozer, AM Lehman, K Maddocks, L Yu, AJ Johnson, JC Byrd Blood, The Journal of the American Society of Hematology 125 (21), 3297-3305, 2015 | 174 | 2015 |
| Interleukin-21 enhances NK cell activation in response to antibody-coated targets JM Roda, R Parihar, A Lehman, A Mani, S Tridandapani, WE Carson The Journal of Immunology 177 (1), 120-129, 2006 | 155 | 2006 |
| A randomized phase 2 trial of bevacizumab with or without daily low-dose interferon alfa-2b in metastatic malignant melanoma KA Varker, JE Biber, C Kefauver, R Jensen, A Lehman, D Young, H Wu, ... Annals of surgical oncology 14, 2367-2376, 2007 | 152 | 2007 |
| CD19 targeting of chronic lymphocytic leukemia with a novel Fc-domain–engineered monoclonal antibody FT Awan, R Lapalombella, R Trotta, JP Butchar, B Yu, DM Benson Jr, ... Blood, The Journal of the American Society of Hematology 115 (6), 1204-1213, 2010 | 150 | 2010 |
